| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/06/2006 | WO2006036074A1 Myostatin isoform |
| 04/06/2006 | WO2006036071A2 Urokinase plasminogen activator receptor targeted contrast agent |
| 04/06/2006 | WO2006035977A1 Ejection liquid, ejection device, ejection cartridge, and method of making droplets from liquid |
| 04/06/2006 | WO2006035936A1 Par-2 antagonists |
| 04/06/2006 | WO2006035923A1 Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus |
| 04/06/2006 | WO2006035702A1 C-peptide specific binding molecule and use thereof |
| 04/06/2006 | WO2006035431A2 Fatty acid modified polylysines as antimicrobial agents |
| 04/06/2006 | WO2006035311A2 GROUP A STREPTOCOCCUS CrgE PROTEIN |
| 04/06/2006 | WO2006035057A1 Modified proteins |
| 04/06/2006 | WO2006034587A1 Rehydration compositions comprising epidermal growth factor |
| 04/06/2006 | WO2006034567A1 Use of compositions comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions |
| 04/06/2006 | WO2006034560A2 Prevention and treatment of mycoplasma-associated diseases |
| 04/06/2006 | WO2006034542A1 Alzheimer's and mild cognitive impairment diagnostics |
| 04/06/2006 | WO2006026470A3 Hiv immunostimulatory compositions |
| 04/06/2006 | WO2006018024A3 Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| 04/06/2006 | WO2006012329A3 Health supplement |
| 04/06/2006 | WO2006009437A3 Use of aspartate for regulating glucose levels in blood |
| 04/06/2006 | WO2006004988A3 B7-dc binding antibody |
| 04/06/2006 | WO2006000753A3 Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer |
| 04/06/2006 | WO2005121328A3 Method for ameliorating an inflammatory skin condition |
| 04/06/2006 | WO2005114216A3 Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 04/06/2006 | WO2005113592A3 Interferon-alpha polypeptides and conjugates |
| 04/06/2006 | WO2005100385A3 Compounds that block the c5a receptor and their use in therapy |
| 04/06/2006 | WO2005098427A3 Method, composition and device for treating starch related diseases |
| 04/06/2006 | WO2005097162A3 Steroid sparing agents and their use |
| 04/06/2006 | WO2005082386A3 Manganese and iron based compounds for elastogenesis and connective tissue treatment |
| 04/06/2006 | WO2005079755A3 Interleukin-13 antagonist powders, spray-dried particles, and methods |
| 04/06/2006 | WO2005077980A3 Soluble tcr-like molecules and their uses |
| 04/06/2006 | WO2005061452A8 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 04/06/2006 | WO2005053795A3 Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| 04/06/2006 | WO2005051799A3 Peptide increasing fusiogenic capacity of a gamete |
| 04/06/2006 | WO2005049065A3 Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
| 04/06/2006 | WO2005027629A3 Regulation of cardiac contractility and heart failure propensity |
| 04/06/2006 | WO2005017127A3 Rna interference compositions and methods |
| 04/06/2006 | WO2004093831A3 Cytokine-expressing cellular vaccine combinations |
| 04/06/2006 | WO2004085617A3 Timp3 as vegf inhibitor |
| 04/06/2006 | WO2003045128A3 SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
| 04/06/2006 | US20060074233 Detect binding with cells transfected with DNA |
| 04/06/2006 | US20060074230 Cartilage matrix protein fusion for use in prevention and treatment of diabetic retinopathy, edema, sepsis and blood disorders |
| 04/06/2006 | US20060074107 Pharmaceutically active piperidine derivatives |
| 04/06/2006 | US20060074080 Combination product comprising melagatran and an anti-arrhythmic oxabispidenes |
| 04/06/2006 | US20060074066 Use of an inhibitor of cathepsin-S or -B to treat or prevent chronic obstructive pulmonary disease |
| 04/06/2006 | US20060074051 comprising a stem cell and a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk protein, and wherein no more than 10% of the amino acids are in D-form |
| 04/06/2006 | US20060074044 Nucleotide sequences coding stem cell factors for use as therapeutic tools in treating learning and memory disorders |
| 04/06/2006 | US20060074043 Antisense modulation of matrix metalloproteinase 1 expression |
| 04/06/2006 | US20060074041 Antisense and antigene therapeutics with improved binding properties and methods for their use |
| 04/06/2006 | US20060074040 Administering an immunostimulatory oligonucleotide or an immunomer compound and treating with ionizing or gamma radiation; antiinflammatory, anticarcinogenic, antitumor, antihistamine, antiallergen, and bronchodilator agents; autoimmune, respiratory system, and skin disorders; cytokine immunotherapy |
| 04/06/2006 | US20060074039 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| 04/06/2006 | US20060074038 Her-2 neu dna vaccine having anti-cancer activity |
| 04/06/2006 | US20060074037 Producing/evaluating a protein/polypeptide (alpha-defensin) with increased antimicrobial activity and stability to effect chemotaxis of T-cells, neutrophil recruitment, or cytokine or interleukin-8 release; immunostimulants; respiratory system disorders; inflammatory bowel disease; viricides; cancer; HIV |
| 04/06/2006 | US20060074036 Agents for gene therapy of cerebrovascular disorders |
| 04/06/2006 | US20060074028 Local, regionally-restricted delivery to an axon in situ of an ubiquitin-proteasome system inhibitor, optionally in conjunction with a microtubule stabilizing reagent, and detection the resultant reduction in axon trauma or axotomyn |
| 04/06/2006 | US20060074027 Microcapsules of luteinizing hormone releasing hormone agonists; glycolic acid-lactic acid copolymers; for treating prostate cancer, prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, dymenorrhea or breast cancer, or inhibiting conception |
| 04/06/2006 | US20060074026 Therapeutic agents and methods for cardiovascular disease |
| 04/06/2006 | US20060074025 Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| 04/06/2006 | US20060074024 Improving heart function by incereasing venturicular contraction using growth hormone |
| 04/06/2006 | US20060074023 Angiogenesis associated proteins, and nucleic acids encoding the same |
| 04/06/2006 | US20060074022 Prevention of primary Sjogren's Syndrome by ICA69 deficiency |
| 04/06/2006 | US20060074021 polymer of positively charged amino acid residues and at least one omega -amino-fatty acid residue; stable, non-toxic and avoiding development of resistance |
| 04/06/2006 | US20060074020 inhibition of angiogenesis and treating tumor with an antitumor biodrug |
| 04/06/2006 | US20060074019 Determining individual dosing regimens by data analysis of variables selected from height, target height, growth velocity, gender, bone age, parental height, plasma levels of insulin-like-growth factor 1, pubertal status, overall health status, environmental factors, and genotype |
| 04/06/2006 | US20060074018 Methods of diagnosing & treating diabetes and insulin resistance |
| 04/06/2006 | US20060074017 Active complex of alpha-lactalbumin (hamlet) and cofactor |
| 04/06/2006 | US20060074016 have effectors with individually distinct biological functions and corresponding activator sites that can each initiate or amplify the biological function of effectors upon context-activation; useful in the diagnosis, prophylaxis, and therapy; minimizing cytotoxicity and drug/antibiotic resistance |
| 04/06/2006 | US20060074015 Enhanced immunosuppressive activity; treatment of ocular allergy, dry eye, and autoimmune and chronic inflammatory diseases, such as asthma, rheumatoid arthritis, multiple sclerosis, psoriasis, and ulcerative colitis |
| 04/06/2006 | US20060074014 Prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer |
| 04/06/2006 | US20060074013 Insulin, insulin-related peptide, and sensitizer; side effect reduction |
| 04/06/2006 | US20060074012 Treatment of gestational diabetes |
| 04/06/2006 | US20060074011 pH above 5.5 may be delivered to a subject with reduced pain |
| 04/06/2006 | US20060074010 Method and apparatus for purifying pharmaceutical compositions using supercritical fluids |
| 04/06/2006 | US20060074009 Natriuretic compounds, conjugates, and uses thereof |
| 04/06/2006 | US20060074008 monoclonal antibody conjugated with peptide drug such as dolastatin derivative |
| 04/06/2006 | US20060074007 Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
| 04/06/2006 | US20060073586 A N-terminal domain, five or six rod repeats, H1 and H4 domains of a dystrophin protein, and a cysteine-rich domain; Duchenne and Becker muscular dystrophies |
| 04/06/2006 | US20060073573 Chemotactic cytokine III |
| 04/06/2006 | US20060073572 Cytokine structurally related to IL-17 |
| 04/06/2006 | US20060073569 Protease for identifying modulators for treatment and prevention of thrombocytopenia and liver disorders |
| 04/06/2006 | US20060073568 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/06/2006 | US20060073567 Novel insulin/IGF/relaxin family polypeptides and DNAs thereof |
| 04/06/2006 | US20060073566 Active modified hedgehog proteins |
| 04/06/2006 | US20060073565 Novel nucleic acid molecules encoding opioid growth factor receptors |
| 04/06/2006 | US20060073564 Nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED) |
| 04/06/2006 | US20060073561 157 human secreted proteins |
| 04/06/2006 | US20060073554 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/06/2006 | US20060073543 Process for the preparation of angiotensis converting enzyme (ACE) inhibitors and its use |
| 04/06/2006 | US20060073522 Derived from ghrelin polypeptide, labelled with fluorochrome and cysteine; drug screening; high throughput assay |
| 04/06/2006 | US20060073518 Method for selecting a candidate drug compound |
| 04/06/2006 | US20060073516 Novel screening method |
| 04/06/2006 | US20060073512 Genomic sequence of the purH gene and purH-related biallelic markers |
| 04/06/2006 | US20060073504 Treatment of pain by inhibition of caspase signaling |
| 04/06/2006 | US20060073498 GlcNAc phosphotransferase of the lysosomal targeting pathway |
| 04/06/2006 | US20060073478 Atlastin |
| 04/06/2006 | US20060073333 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 04/06/2006 | US20060073281 Polyethylene glycol diacrylate dispersion crosslinked by N-isopropylacrylamide in an emulsion forms microspheres; loading cytokines for drug delivery without deactivating; solvent-free;time-release agents; bioavailability; anticarcinogenic, -tumor agents; cytokine; tissue-targeted therapy |
| 04/06/2006 | US20060073207 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 04/06/2006 | US20060073193 Enzyme granules |
| 04/06/2006 | US20060073186 Nutritional compositions |
| 04/06/2006 | US20060073178 injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss |
| 04/06/2006 | US20060073176 Water-soluble composition containing coenzyme q10 |
| 04/06/2006 | US20060073169 Acellular antibordetella vaccine |